The scientific goal of the Hollings Cancer Center (HCC) Developmental Cancer Therapeutics (DCT) Program is to discover and characterize unique agents and pathways that will impact the development of more effective cancer therapies and to translate these discoveries into clinical applications by using proof-of principle, early phase clinical and correlative science studies. The DCT Program is co-led by Kenneth D. Tew, PhD and Carolyn D. Britten, MD. The DCT Program is organized around three themes of scientific investigation: ? Elucidation of Cellular Signaling Pathways. ? Modulation of Redox and Cellular Stress Response. ? Development of Small Molecule Chemotherapeutic Agents. The 46 members of the DCT Program, representing 12 departments within the College of Medicine and the College of Pharmacy, have 87 active grants/contracts totaling $11.7M in cancer research funding ($7.7 in peer-reviewed funding and $3.7M from the NCI). In 2012 the DCT Program implemented 65 early phase (pilot. Phase I, Phase l/ll, and Phase II) interventional treatment clinical trials, of which 25 were invesfigator initiated;224 patients were enrolled onto all DCT Program interventional treatment studies. In the past five years, DCT Program members produced 305 cancer-focused publications with 17% of these representing inter-programmatic and 35% intra-programmatic collaborations and 48% from mulfi-insfitutional collaborations.

Public Health Relevance

Members of the Developmental Cancer Therapeutics Program are linked by synergistic research interests with a focus on drug discovery and development. Collaborations between this program's clinical and laboratory investigators are leading to development of new clinical cancer trials.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Medical University of South Carolina
United States
Zip Code
Song, J H; An, N; Chatterjee, S et al. (2015) Deletion of Pim kinases elevates the cellular levels of reactive oxygen species and sensitizes to K-Ras-induced cell killing. Oncogene 34:3728-36
Zemskova, Marina Y; Song, Jin H; Cen, Bo et al. (2015) Regulation of prostate stromal fibroblasts by the PIM1 protein kinase. Cell Signal 27:135-46
Boppana, Nithin B; Kodiha, Mohamed; Stochaj, Ursula et al. (2014) Ceramide synthase inhibitor fumonisin B1 inhibits apoptotic cell death in SCC17B human head and neck squamous carcinoma cells after Pc4 photosensitization. Photochem Photobiol Sci 13:1621-7
God, Jason M; Zhao, Dan; Cameron, Christine A et al. (2014) Disruption of HLA class II antigen presentation in Burkitt lymphoma: implication of a 47,000 MW acid labile protein in CD4+ T-cell recognition. Immunology 142:492-505
Fuseler, John W; Robichaux, Jacqulyne P; Atiyah, Huda I et al. (2014) Morphometric and fractal dimension analysis identifies early neoplastic changes in mammary epithelium of MMTV-cNeu mice. Anticancer Res 34:1171-7
Esnaola, Nestor F; Chaudhary, Uzair B; O'Brien, Paul et al. (2014) Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 88:837-44
Chen, Weiqin; Zhou, Hongyi; Saha, Pradip et al. (2014) Molecular mechanisms underlying fasting modulated liver insulin sensitivity and metabolism in male lipodystrophic Bscl2/Seipin-deficient mice. Endocrinology 155:4215-25
Hussey, Sophie E; Lum, Helen; Alvarez, Andrea et al. (2014) A sustained increase in plasma NEFA upregulates the Toll-like receptor network in human muscle. Diabetologia 57:582-91
He, Huacheng; Cattran, Alexander W; Nguyen, Tu et al. (2014) Triple-responsive expansile nanogel for tumor and mitochondria targeted photosensitizer delivery. Biomaterials 35:9546-53
Kesarwani, Pravin; Al-Khami, Amir A; Scurti, Gina et al. (2014) Promoting thiol expression increases the durability of antitumor T-cell functions. Cancer Res 74:6036-47

Showing the most recent 10 out of 162 publications